Disclosures for "The Phase 2, Randomized, Placebo-controlled PRECEDENT Trial of SAGE-718 in Patients With Parkinson's Disease Cognitive Impairment: Clinical Trial in Progress")
-
Dr. Bullock has received personal compensation for serving as an employee of Sage Therapeutics, Inc. . Dr. Bullock has stock in Sage Therapeutics, Inc.
-
Aaron Koenig has received personal compensation for serving as an employee of Sage Therapeutics.
-
Dr. Paumier has nothing to disclose.
-
Ms. Freitag has nothing to disclose.
-
Jeffrey Wald has received personal compensation for serving as an employee of Sage Therapeutics. Jeffrey Wald has received stock or an ownership interest from Sage Thereapeutics.
-
Dr. Park has nothing to disclose.
-
Michael Quirk has received personal compensation for serving as an employee of Sage Therapeutics. Michael Quirk has received stock or an ownership interest from Sage Therapeutics.
-
Jennifer Petrillo, 14951 has received personal compensation for serving as an employee of Sage Therapeutics. Jennifer Petrillo, 14951 has received stock or an ownership interest from Sage Therapeutics.
-
Dr. Doherty has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Doherty has received stock or an ownership interest from Sage Therapeutics.